Pharmacogenomics of cardiovascular drugs
© Adithan; licensee BioMed Central Ltd. 2014
Published: 21 January 2014
Cardiovascular diseases account for the second largest number of non-communicable disease after mental illnesses. Coronary heart diseases, hypertension, atherosclerosis, congestive heart failure, arrhythmias are important cardiovascular diseases. Beta blockers, statins, antiplatelet drugs, anticoagulants, drugs modifying renin angiotensin systems and many others are being used for treating these ailments. Still, satisfactory treatment of these diseases is still elusive. Drug response in influenced by many environmental factors besides host factor. Besides the above, genetic factor is also important in modifying response to cardiovascular drugs. Now there is reasonable amount of evidence exists that Indian population is genetically distinct from other major ethnic groups. The allele and genotype frequencies of genes encoding important drug metabolizing enzymes, drug transporters and receptors of Indian population are different from Caucasians and Orientals. Studies done in our laboratory and other Indian laboratories suggested that pharmacogenomics of clopidogrel, warfarin, acenocoumarol, beta blockers etc. may have clinical significance in treating cardiovascular diseases of Indian population. There is a need for multi-institutional and multi-disciplinary approach for large scale implementation of pharmacogenomics and personalized medicines in cardiovascular diseases.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.